Art. -Nr.: HY-13991

CCG-1423

15 Cited Publications

Kundenbewertung

Based on 15 publication(s) in Google Scholar

CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.88%
CAS. Nr.: 285986-88-1
Formel: C₁₈H₁₃ClF₆N₂O₃
Molecular Weight:454.75

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

CCG-1423 Chemical Structure

CAS. Nr.: 285986-88-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 1.5 µM (Rho-pathway selective serum response element-luciferase reporter)^[1]

Alle Ras Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	29.8 μM Compound: CCG-1423	Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
H9c2	IC₅₀	35.5 μM Compound: CCG-1423	Antiproliferative activity against rat H9c2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against rat H9c2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
HCT-116	IC₅₀	20.5 μM Compound: CCG-1423	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
HCT-15	IC₅₀	37.5 μM Compound: CCG-1423	Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
HEK293	IC₅₀	55.4 μM Compound: CCG-1423	Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
L02	IC₅₀	30.4 μM Compound: CCG-1423	Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
SW480	IC₅₀	41.3 μM Compound: CCG-1423	Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
SW-620	IC₅₀	15.5 μM Compound: CCG-1423	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]

In Vitro

CCG-1423 (10 μM; 24 h) affects invasion by cultured PC-3 cells into a Matrigel matrix and inhibits 54% mitochondrial metabolism of WST-1^[1].
CCG-1423 (0-100 μM; 24 h) inhibits RhoA and RhoC signaling pathways with an IC₅₀ value of 1.5 μM for Rho-pathway selective serum response element-luciferase reporter^[1].
CCG-1423 (1 μM; 16 h) improves glucose uptake in both L6 cells and primary human myotubes^[2].
CCG-1423 (10 μM; 18-19 h) inhibits expression of Rho downstream^[2].
CCG-1423 (3 μM; 25 h) selectively stimulates apoptosis of RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Invasion Assay^[1]

Cell Line:

PC-3 cell line
Concentration:

10 µM
Incubation Time:

24 hours
Result:

Inhibited 71% invasion by cultured PC-3 cells into a Matrigel matrix.

Western Blot Analysis^[2]

Cell Line:

L6 myotubes
Concentration:

1 µM
Incubation Time:

48 hours
Result:

Increased insulin-stimulated Akt phosphorylation, blocked ERK phosphorylation, and increased IRS-1 tyrosine phosphorylation and its association with the p85 regulatory subunit of PI3K.

Cell Proliferation Assay^[3]

Cell Line:

PC-3 cell line
Concentration:

0.3 µM
Incubation Time:

8 days
Result:

Inhibited growth of PC-3 prostate cancer cells with an IC₅₀ value of 1 µM with 30 µM LPA adding.

Apoptosis Analysis^[3]

Cell Line:

RhoC-overexpressing A375M2 and low RhoC-expressing A375 melanoma cell lines
Concentration:

3 µM
Incubation Time:

25 hours
Result:

Stimulated apoptosis of A375M2 cell line compared with the parental cell line.

In Vivo

CCG-1423 (0.15 mg/kg; i.p. once daily for two weeks) affects glucose tolerance and insulin levels in HFD-fed mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

16-week-old mice with HFD-induced obesity^[1]
Dosage:

0.15 mg/kg
Administration:

Intraperitoneal injection; 0.15 mg/kg once per day; for two weeks
Result:

Improved glucose tolerance and reduced insulin levels at 30 minutes after glucose injection.

Chemical Information

CAS. Nr. 285986-88-1
Appearance Solid
Molecular Weight 454.75
Formel C₁₈H₁₃ClF₆N₂O₃
Color White to off-white
SMILES

O=C(NOC(C)C(NC1=CC=C(Cl)C=C1)=O)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (15)

All

Sort by:

Journal Impact Factor

Exp Mol Med

Glia maturation factor beta deficiency protects against diabetic osteoporosis by suppressing osteoclast hyperactivity. [Abstract]

2023 May;55(5):898-909. PMID: 37121966
Redox Biol

Myo1f regulates monocyte adhesion and contributes to atherosclerosis via MRTFA-dependent ITGB2 expression. [Abstract]

2026 Mar:90:104049. PMID: 41610517
Clin Transl Med

Uterus globulin associated protein 1 (UGRP1) binds podoplanin (PDPN) to promote a novel inflammation pathway during Streptococcus pneumoniae infection. [Abstract]

2022 Jun;12(6):e850. PMID: 35652821
Cell Rep

Lysophosphatidic acid and sphingosine-1-phosphate are apical polarity cues in multiple organoid systems. [Abstract]

2025 Jun 10;44(6):115842. PMID: 40503936
Cell Rep

ENKD1 modulates innate immune responses through enhanced geranylgeranyl pyrophosphate synthase activity. [Abstract]

2025 Mar 5;44(3):115397. PMID: 40048432
Cell Biosci

ACTA1 is inhibited by PAX3-FOXO1 through RhoA-MKL1-SRF signaling pathway and impairs cell proliferation, migration and tumor growth in Alveolar Rhabdomyosarcoma. [Abstract]

2021 Jan 28;11(1):25. PMID: 33509264
Life Sci

Macrophage MKL1 contributes to cardiac fibrosis in a mouse model of myocardial infarction. [Abstract]

2024 Aug 31:123036. PMID: 39222836
Commun Biol

A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells. [Abstract]

2021 Mar 25;4(1):399. PMID: 33767353
Cancers (Basel)

Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer. [Abstract]

2020 Nov 27;12(12):3540. PMID: 33260953
iScience

RSK1-SRF signaling axis drives fibroblast activation and pulmonary fibrosis: Genetic causality and therapeutic targeting. [Abstract]

2026 Mar 30;29(5):115495. PMID: 42004028
Theriogenology

Influence of Wilms' tumor suppressor gene WT1 on bovine Sertoli cells polarity and tight junctions via non-canonical WNT signaling pathway. [Abstract]

2019 Oct 15:138:84-93. PMID: 31302435
Tissue Eng Part A

The inhibitory effect of RADKPS on pyroptosis of nucleus pulposus-derived mesenchymal stem cells. [Abstract]

2023 Aug;29(15-16):424-438. PMID: 37279291
Arch Dermatol Res

Annexin A1 protects epidermal stem cells against ultraviolet-B irradiation-induced mitochondrial dysfunction. [Abstract]

2024 Jun 14;316(7):385. PMID: 38874830
Reprod Fertil Dev

Wilms' tumour 1 (WT1) negatively regulates the expression of connexin 43 via a non-canonical Wnt signalling pathway in cultured bovine Sertoli cells. [Abstract]

2020 Mar;32(5):522-530. PMID: 32023428
bioRxiv

Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in mice. [Abstract]

2024 Dec 5:2024.12.04.626665. PMID: 39677616

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (219.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1990 mL

10.9951 mL

21.9901 mL

5 mM

0.4398 mL

2.1990 mL

4.3980 mL

10 mM

0.2199 mL

1.0995 mL

2.1990 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Korean - KR (604 KB)
- Portuguese - PT (604 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72. [Content Brief]

[2]. Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29. [Content Brief]

[3]. Evelyn CR, et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007 Aug;6(8):2249-60. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1990 mL	10.9951 mL	21.9901 mL	54.9753 mL
	5 mM	0.4398 mL	2.1990 mL	4.3980 mL	10.9951 mL
	10 mM	0.2199 mL	1.0995 mL	2.1990 mL	5.4975 mL
	15 mM	0.1466 mL	0.7330 mL	1.4660 mL	3.6650 mL
	20 mM	0.1100 mL	0.5498 mL	1.0995 mL	2.7488 mL
	25 mM	0.0880 mL	0.4398 mL	0.8796 mL	2.1990 mL
	30 mM	0.0733 mL	0.3665 mL	0.7330 mL	1.8325 mL
	40 mM	0.0550 mL	0.2749 mL	0.5498 mL	1.3744 mL
	50 mM	0.0440 mL	0.2199 mL	0.4398 mL	1.0995 mL
	60 mM	0.0367 mL	0.1833 mL	0.3665 mL	0.9163 mL
	80 mM	0.0275 mL	0.1374 mL	0.2749 mL	0.6872 mL
	100 mM	0.0220 mL	0.1100 mL	0.2199 mL	0.5498 mL

Keywords

CCG-1423

15 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CCG-1423

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glutamine Metabolism Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) CCG-1423

Alle Ras Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CCG-1423

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glutamine Metabolism Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) CCG-1423

Alle Ras Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CCG-1423 Related Classifications

HY-13991 Related Classifications